chartexchange

Cardiff Oncology Reports Third Quarter 2026 Results and Provides Business Update

GlobeNewswire Inc. | Nov 12, 2026 7:00 AM EST

Phase 2 trial remains ongoing, with median PFS not reached in the 30 mg onvansertib + FOLFIRI/bev arm versus median PFS of approximately 11 months in the combined SoC arms

Read original article